MENU
+Compare
DNLI
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$14.10
Change
-$0.39 (-2.69%)
Capitalization
2.05B

DNLI Denali Therapeutics Forecast, Technical & Fundamental Analysis

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease... Show more

Industry: #Biotechnology
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for DNLI with price predictions
Jun 27, 2025

DNLI sees its Stochastic Oscillator recovers from oversold territory

On June 25, 2025, the Stochastic Oscillator for DNLI moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 71 instances where the indicator left the oversold zone. In of the 71 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DNLI advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on DNLI as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for DNLI turned negative on June 20, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

DNLI moved below its 50-day moving average on June 27, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for DNLI crossed bearishly below the 50-day moving average on June 26, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNLI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

DNLI broke above its upper Bollinger Band on June 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for DNLI entered a downward trend on June 06, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. DNLI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.823) is normal, around the industry mean (16.377). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). DNLI's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. DNLI's P/S Ratio (3333.333) is very high in comparison to the industry average of (252.527).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNLI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

DNLI is expected to report earnings to fall 8.64% to -71 cents per share on July 31

Denali Therapeutics DNLI Stock Earnings Reports
Q2'25
Est.
$-0.71
Q1'25
Missed
by $0.08
Q4'24
Beat
by $0.17
Q3'24
Missed
by $0.03
Q2'24
Beat
by $0.08
The last earnings report on May 06 showed earnings per share of -77 cents, missing the estimate of -69 cents. With 4.08M shares outstanding, the current market capitalization sits at 2.05B.
A.I. Advisor
published General Information

General Information

a biotechnology company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
161 Oyster Point Boulevard
Phone
+1 650 866-8548
Employees
445
Web
https://www.denalitherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ARGFX71.370.51
+0.72%
Ariel Fund Investor
NOSIX62.560.33
+0.53%
Northern Stock Index
IJPTX14.320.05
+0.35%
VY® JPMorgan Emerging Markets Equity S2
COVAX12.840.01
+0.08%
Columbia Small Cap Value II A
AGIRX19.89N/A
N/A
Alger Mid Cap Growth Institutional R

DNLI and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-2.69%
BEAM - DNLI
61%
Loosely correlated
-1.98%
NRIX - DNLI
59%
Loosely correlated
+0.17%
RGNX - DNLI
58%
Loosely correlated
-4.11%
ARWR - DNLI
57%
Loosely correlated
+0.06%
ATXS - DNLI
57%
Loosely correlated
+2.39%
More